 Cohorts of 3-6 patients receive escalating doses of stem cell factor until the maximum tolerated dose MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional cohort of 3 patients receives treatment at the MTD. 